account_id none on file
legal_name Korsana Biosciences, Inc.
ticker CYCN
cik 1755237
domain cyclerion.com
linkedin_company_url https://www.linkedin.com/company/cyclerion
entry_point_account_id none on file
name Cyclerion Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 7 executives 2 family 0
why_nownone on file
callsnone on file
filings
All members of the Board are also reimbursed for reasonable and documented out-of-pocket travel and lodging expenses incurred in connection with attending meetings and activities of the Board and its committees.
filing / Sep 11, 2026 / receipt
We recognized revenue of $0.1 million and $0.2 million related to the Option extension fee and expense reimbursement during the three and six months ended June 30, 2025, respectively.
filing / Aug 4, 2026 / receipt
The Company recognized revenue of $ 0.1 million and $ 0.2 million related to the extension fee payment and expense reimbursement for the three and six months ended June 30, 2025, respectively.
filing / Aug 4, 2026 / receipt
Under ASC 205-40, the future receipt of potential funding from future partnerships, license payments, equity or debt issuances, certain cost reduction measures and the achievement of potential milestone payments from Akebia cannot be considered probable at this time because these plans are not entirely within the Company’s control and/or have not been approved by the Board of Directors as of the date of these condens
filing / Aug 4, 2026 / receipt
We recognized revenue of $0.1 million related to the Option extension fee and expense reimbursement during the three months ended March 31, 2025.
filing / May 12, 2026 / receipt
The Company recognized revenue of $ 0.1 million related to the extension fee payment and expense reimbursement for the three months ended March 31, 2025.
filing / May 12, 2026 / receipt
Under ASC 205-40, the future receipt of potential funding from future partnerships, license payments, equity or debt issuances, certain cost reduction measures and the achievement of potential milestone payments from Akebia cannot be considered probable at this time because these plans are not entirely within the Company’s control and/or have not been approved by the Board of Directors as of the date of these condens
filing / May 12, 2026 / receipt
executives
| Anjeza Gjino | Chief Financial Officer | receipt | |
| Cheryl Gault | Chief Operating Officer | - | receipt |
familynone on file
upcomingnone on file
changes
| 2020-12-21 | Chief Financial Officer, appointed | sec_8k |
| 2020-12-21 | Chief Operating Officer, appointed | sec_8k |
| 2019-04-02 | President, departed | sec_8k |
mcp_package_hint
slug cyclerion-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$